Trial · NCT03688685
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03688685, Phase 2, Completed, Cadent Therapeutics; results first posted 2021-07-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study to Evaluate CAD-1883 in Essential Tremor. Trials, record NCT03688685. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03688685
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study to Evaluate CAD-1883 in Essential Tremor
- NCT number
- NCT03688685
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Cadent Therapeutics
- Conditions
- Essential Tremor
- Interventions
- CAD-1883
- First posted
- 2018-09-28
- Last updated
- 2021-08-05
- Results first posted
- 2021-07-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Time of signed informed consent until 21 days after first treatment | Number of subjects who experienced TEAEs and the severity of those TEAEs. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Time of signed informed consent until 21 days after first treatment | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Open-label Study of CAD-1883 | Subjects with at least 1 TAE | 13 | participants | |
| Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Open-label Study of CAD-1883 | Subjects with Mild AE | 9 | participants | |
| Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Open-label Study of CAD-1883 | Subjects with Moderate AE | 2 | participants | |
| Evaluate the Occurrence and Severity of Treatment Emergent AEs. | Open-label Study of CAD-1883 | Subjects with Severe AE | 2 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Open-label Study of CAD-1883 | 25 | |
| Overall Study | COMPLETED | Open-label Study of CAD-1883 | 21 | |
| Overall Study | NOT COMPLETED | Open-label Study of CAD-1883 | 4 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Open-label Study of CAD-1883 | 2 | 25 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Open-label Study of CAD-1883 | 0 | 25 |
| Total, other adverse events | Open-label Study of CAD-1883 | 2 | 25 |
| Total, serious adverse events | Open-label Study of CAD-1883 | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03688685
GET https://conductscience.org/api/trials/v1/NCT03688685/registered